Lightwave Logic Re-Confirms Previous r33 Test Results of its 'Next Generation Electro-Optic Material Platform'

Lightwave Logic, Inc. (OTC Bulletin Board: LWLG), a development stage company, moving toward prototype demonstration and commercialization of its high-activity, high-stability organic polymers for applications in electro-optical device markets, announced today current tests results support the earlier results (r33) of its Perkinamine class materials.

Our most recent performance testing (r33) measurements conducted by Dr. C.C. Teng, the r33 Teng-Man testing protocol, support our previous test results which ranged from three to seven times the performance of competitive materials. The tests were conducted at 1350 and 1550 nano-meters (nm).

Lightwave is continuing with its independent performance testing and material characterization of our "Next Generation Electro-Optic Material Platform" using among others Johns Hopkins University and the University of Alabama. Professor John D. Tovar at Johns Hopkins University is characterizing our Perkinamine class of materials using spectroelectrochemical methods, while the University of Alabama is characterizing our Perkinamine class of materials using electro spin resonance spectroscopy.

Fred Goetz, Jr., Lightwave's Chief Science Officer, stated, "We believe we have created the first electro-optic polymer material platform to exhibit the ability to support a broad range of applications with thermal stability as high as 350 degrees Celsius. This high temperature stability of our materials eliminates a major obstacle to vertical integration of electro-optic polymers into standard microelectronic manufacturing processes."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.